Skip to content
Search

Latest Stories

Mass-testing reduced Liverpool Covid-19 cases by a fifth, study finds

A mass rapid-testing scheme reduced Covid-19 cases in Liverpool by more than a fifth, researchers said on Wednesday, arguing it was an effective public health intervention despite concerns over accuracy of the devices.

The community testing pilot scheme launched in November, and offered everyone in the city tests whether or not they had symptoms, in an attempt to find a new way to use testing to limit the spread of the coronavirus.


The study, led by the University of Liverpool with government backing, concluded that community testing led to an 18 per cent increase in case detection and a 21 per cent reduction in cases compared with other areas up to mid-December.

The spread of the Alpha variant first identified in Kent made comparisons between areas more difficult after that point, the researchers said.

"The Liverpool pilot showed that community testing can work, and it works well if it is nationally flexible and locally grounded," Iain Buchan, the University of Liverpool professor leading the trial, told reporters.

Some scientists have questioned the use of rapid lateral flow tests, saying they might do more harm than good, and the U.S. regulator has warned that the performance of the Innova test in use in Britain has not been adequately established.

Despite concerns about the lower accuracy of lateral flow tests compared to PCR tests, the Liverpool researchers said that the devices identified most cases with a high viral load.

The rapid turnaround times had a benefit too, as lateral flow tests give a result in 30 minutes, rather than needing to be processed in a laboratory.

"If it's positive, (people) get immediate reinforcement that they need to take action... we can see it drove down cases," said Calum Semple, Professor of Outbreak Medicine, University of Liverpool.

As part of the study, 283,338 Liverpool residents took a test using a lateral flow device between Nov 6 2020 and April 30 2021.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less